Log in to search using one of your social media accounts:


MyoKardia ’s Phase II trial for oHCM drug meets endpoints

MyoKardia has reported positive top-line results from the first cohort of its Phase II PIONEER-HCM clinical trial of mavacamten in patients with symptomatic, obstructive hypertrophic cardiomyopathy (oHCM).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news

Related Links:

More News: Cardiology | Cardiomyopathy | Clinical Trials | Heart | Hypertrophic Cardiomyopathy | Pharmaceuticals